Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

<p>TRAEs (reported as PTs) in ≥20% of patients, grade ≥3 TRAEs in ≥5% of patients, and AESIs in ≥10% of patients in the dose-expansion phase.</p>

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awdur: Kristoffer Staal Rohrberg (15009138) (author)
Awduron Eraill: Juanita S. Lopez (22687839) (author), Mohammed M. Milhem (15352499) (author), Christian U. Blank (14850778) (author), Irene Reijers (22687842) (author), Fiona Thistlethwaite (22687845) (author), Ruth Plummer (15028641) (author), Sarina A. Piha-Paul (15294428) (author), Pasi A. Jänne (14954872) (author), Elaine Shum (14955138) (author), Heather M. Shaw (22687848) (author), Philip R. Debruyne (20432881) (author), Cristopher Lao (22687851) (author), Jean-Francois Baurain (15031089) (author), Jennifer H. Choe (15052775) (author), Eelke Gort (17740951) (author), Yujie Zhao (22687854) (author), Guy Jerusalem (15017648) (author), Patrick Schöffski (15013461) (author), Andrew William Chen (22687857) (author), Eric A. Cohen (15017996) (author), Walter C. Mankowski (22687860) (author), Leonid Roshkovan (22687863) (author), Sharyn I. Katz (22687866) (author), Despina Kontos (15018005) (author), Lauren K. Brady (22687869) (author), Mohammed Qutaish (22687872) (author), Patricia Garrido Castro (22687875) (author), Nora Pencheva (22687878) (author), Gaurav Bajaj (22687881) (author), Yali Fu (22687884) (author), Kristian Windfeld (22687887) (author), Panagiota Reiter (22687890) (author), Maria Jure-Kunkel (15117740) (author), Brandon W. Higgs (15035279) (author), Katayoun I. Amiri (22687893) (author), Tahamtan Ahmadi (22687896) (author), Ulf Forssmann (22687899) (author), Suresh S. Ramalingam (14951413) (author), Ignace Vergote (15027870) (author)
Cyhoeddwyd: 2025
Pynciau:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Immunology
Antibodies/immunoconjugates
Lung Cancer
Melanoma
Ovarian Cancer
Sarcomas
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
Disgrifiad
Crynodeb:<p>TRAEs (reported as PTs) in ≥20% of patients, grade ≥3 TRAEs in ≥5% of patients, and AESIs in ≥10% of patients in the dose-expansion phase.</p>

Eitemau Tebyg